Where serious patients
compare notes.
A peer community for working patients in metabolic and recovery peptides. Protocol threads, lab-day Q&A with practicing clinicians, weekly journal clubs, and a fast Discord that doesn't pretend to be a marketplace.
Code of conduct.
A peer space for working patients — held to the standards of a real lab meeting.
1. Verification is real
Membership is verified against ORCID, institutional email, or published authorship. Misrepresentation is grounds for permanent removal.
2. Cite, don't assert
Claims about pharmacokinetics, mechanism, or outcomes need a citation, a methods note, or an explicit "anecdote" tag.
3. No medical advice
This is a research community. Do not request or offer dosing recommendations for human use. The compounds are research-use-only.
4. Disclose conflicts
If you have a financial interest in a vendor or therapy you're discussing, say so in the post.
5. Respect protocols, not personalities
Critique methodology vigorously. Do not attack the person. Mods will warn once, then suspend.
6. Privacy of subjects
Anonymize all field-report data. Never post identifying details about research subjects, even in DMs.
7. Element MD is not in the room
Element MD employees do not moderate scientific debate. Mods are practicing patients, listed publicly. Disagreement with Element MD's lab brief is welcome and encouraged.
Protocol discussions, this week.
Where members are sharing dosing schedules, comparing readouts across labs, and debugging methodology. Pinned by the moderator team based on activity and signal-to-noise.
The 6-week titration playbook — open for review
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
EMERALD-2 readout: thread for full publication watch
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
DXA reproducibility: anyone seeing drift on Hologic Horizon at week 80+?
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
Cycled vs. continuous dosing — does anyone have chronic data?
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
Reconstitution practices: BAC water sourcing & sterility verification
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
Statistical handling of dropout in long-duration cessation arms
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
BPC-157 + TB-500 stacking — methodology for non-confounded readouts
Posting our internal incretin titration playbook for community feedback before we formalize it as a Element MD-published methods note. Six steps, weekly increments, explicit hold criteria at each step...
Live sessions with practicing clinicians.
Every Thursday at 16:00 ET, a verified clinician or patient fields questions from the community for an hour. Replays archived for verified members.
Reading the EMERALD-2 readout — what the press release missed
Titration schedules for triple-agonist research — a working session
GIP/GLP-1 mechanism deep dive — and the open mechanistic questions
Body composition by DXA — methodology and pitfalls
BPC-157 evidence base — where the science actually stands
Statistical methods for incretin trials — a primer
Ask this week's expert.
Reviewed by the Lab-Day team. The best questions are answered live; everything else gets a written reply within 5 days.
The people who keep this place serious.
Translational pharmacologist focused on protocol design for peptide therapeutics. Maintains the community titration playbook.
Practicing internist and clinical trial methodologist. Runs the Trial Watch column and the EMERALD-2 watch thread.
Practicing endocrinologist and translational patient. 16 years on metabolic disease and incretin pharmacology.
Body-composition methodologist. Maintains the methods reference library and runs the DXA reproducibility working group.
Top contributor on lab gear & reconstitution practices. Six years running shared lab core; opinionated about COAs.
Biostatistician focused on long-duration metabolic trials. Goes very deep on dropout handling and pre-spec analysis.
Recovery medicine. Runs the BPC-157 / TB-500 working group. Surgically careful about evidence base.
Sports medicine. The community's go-to on tendinopathy protocols and recovery readouts in athlete populations.
Join the community.
Verification takes 1–2 business days. We check institutional affiliation, ORCID where applicable, and review a short statement of research interest. Free for verified researchers; the community is funded by Element MD Research with no vendor influence on moderation.